Bronfman E.L. Rothschild L.P. grew its position in Allergan PLC. (NYSE:AGN) by 16.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,177 shares of the company’s stock after buying an additional 718 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Allergan PLC. were worth $1,061,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Allergan PLC. by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after buying an additional 482,220 shares during the period. Northern Trust Corp raised its position in shares of Allergan PLC. by 8.8% in the 2nd quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after acquiring an additional 364,722 shares in the last quarter. Epoch Investment Partners Inc. raised its position in shares of Allergan PLC. by 3.8% in the 1st quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after acquiring an additional 73,081 shares in the last quarter. Blue Ridge Capital L.L.C. raised its position in shares of Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after acquiring an additional 370,400 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Allergan PLC. by 3.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,668,088 shares of the company’s stock worth $405,510,000 after acquiring an additional 63,173 shares in the last quarter. Institutional investors and hedge funds own 81.65% of the company’s stock.
Several research analysts recently issued reports on the company. Morgan Stanley lowered Allergan PLC. from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $284.00 to $228.00 in a research report on Wednesday, September 20th. J P Morgan Chase & Co set a $275.00 target price on Allergan PLC. and gave the company a “buy” rating in a research report on Sunday, October 22nd. Cowen and Company reaffirmed an “outperform” rating and set a $400.00 target price on shares of Allergan PLC. in a research report on Tuesday, August 29th. Zacks Investment Research lowered Allergan PLC. from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating on shares of Allergan PLC. in a research report on Monday, September 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $246.73.
Allergan PLC. (NYSE AGN) traded up $4.20 during mid-day trading on Wednesday, reaching $174.87. The company’s stock had a trading volume of 1,828,083 shares, compared to its average volume of 2,910,292. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The firm has a market capitalization of $56,760.00, a PE ratio of 11.10, a price-to-earnings-growth ratio of 1.08 and a beta of 1.12. Allergan PLC. has a one year low of $169.61 and a one year high of $256.80.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.32 earnings per share. analysts predict that Allergan PLC. will post 16.28 EPS for the current fiscal year.
Allergan PLC. declared that its board has approved a stock repurchase program on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.60%. Allergan PLC.’s dividend payout ratio is currently -12.39%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.